Cliquer ici pour toutes les publications du CNR-MyRMA en 2015
1368488
9FTWPRVV
items
1
art-libraries-society-of-north-america-arlisna-reviews
0
default
asc
236
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-53a9c2edcb259717838699b496f72786%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229FTWPRVV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222015-01-15%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%26%23x201C%3BCompassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%26%23x201D%3B%20by%20Lorenzo%20Guglielmetti%20et%20al.%20%3Ci%3EClinical%20Infectious%20Diseases%3C%5C%2Fi%3E.%2060%2C%20no.%202%20%28January%2015%2C%202015%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Compassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22M%5Cu00e9tivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chadelat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dautzenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Rivoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Appere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Assouline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Borie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boukari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Caseris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Douadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Dumoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Duval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20F.%22%2C%22lastName%22%3A%22Faucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gallien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Godet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Le%22%2C%22lastName%22%3A%22Grusse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Naccache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Philippe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Richaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Saad%22%7D%5D%2C%22abstractNote%22%3A%22Background.%20Bedaquiline%20is%20a%20new%20antibiotic%20that%20was%20approved%20for%20the%20treatment%20of%20multidrug-resistant%20%28MDR%29%20tuberculosis.%20We%20aimed%20to%20evaluate%20the%20short-term%20microbiological%20efficacy%20and%20the%20tolerability%20profile%20of%20bedaquiline.%5CnMethods.%20We%20performed%20a%20retrospective%20cohort%20study%20among%20patients%20with%20MDR%20tuberculosis%20receiving%20bedaquiline%20for%20compassionate%20use%20between%20January%202010%20and%20July%202013%20and%20evaluated%20at%206%20months%20of%20bedaquiline%20treatment.%5CnResults.%20A%20total%20of%2035%20patients%20with%20MDR%20tuberculosis%20were%20included%20in%20the%20study.%20Nineteen%20%2854%25%29%20had%20extensively%20drug-resistant%20%28XDR%29%20tuberculosis%2C%20and%2014%20%2840%25%29%20had%20isolates%20resistant%20to%20fluoroquinolones%20%28Fqs%29%20or%20second-line%20injectables.%20Bedaquiline%20was%20associated%20with%20a%20median%20of%204%20%28range%2C%202%5Cu20135%29%20other%20drugs%2C%20including%20linezolid%20in%2033%20%2894%25%29%20cases.%20At%206%20months%20of%20bedaquiline%20treatment%2C%20culture%20conversion%20was%20achieved%20in%2028%20of%2029%20%2897%25%29%20cases%20with%20culture-positive%20pulmonary%20tuberculosis%20at%20bedaquiline%20initiation.%20Median%20time%20to%20culture%20conversion%20was%2085%20days%20%28range%2C%208%5Cu2013235%20days%29.%20Variables%20independently%20associated%20with%20culture%20conversion%20were%20treatment%20with%20a%20Fq%20%28P%20%3D%20.01%29%2C%20absence%20of%20lung%20cavities%20%28P%20%3C%20.001%29%2C%20and%20absence%20of%20hepatitis%20C%20virus%20infection%20%28P%20%3D%20.001%29.%20A%20total%20of%207%20patients%20%2820%25%29%20experienced%20a%20%5Cu226560-ms%20increase%20in%20QT%20interval%2C%20leading%20to%20bedaquiline%20discontinuation%20in%202%20%286%25%29%20cases.%20Severe%20liver%20enzyme%20elevation%20occurred%20in%202%20patients%20%286%25%29.%20During%20the%20study%20period%2C%201%20death%20%283%25%29%20occurred%20and%20was%20reported%20as%20unrelated%20to%20tuberculosis%20or%20antituberculosis%20treatment.%5CnConclusions.%20The%20use%20of%20bedaquiline%20combined%20with%20other%20active%20drugs%20has%20the%20potential%20to%20achieve%20high%20culture%20conversion%20rates%20in%20complicated%20MDR%20and%20XDR%20tuberculosis%20cases%2C%20with%20a%20reassuring%20safety%20profile%20at%206%20months%20of%20treatment.%22%2C%22date%22%3A%222015-01-15%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciu786%22%2C%22ISSN%22%3A%221058-4838%2C%201537-6591%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcid.oxfordjournals.org%5C%2Fcontent%5C%2F60%5C%2F2%5C%2F188%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A55%3A16Z%22%7D%7D%5D%7D
“Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort” by Lorenzo Guglielmetti et al. Clinical Infectious Diseases. 60, no. 2 (January 15, 2015). https://doi.org/10.1093/cid/ciu786.